Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Deep Lens (acquired by Paradigm) logo — Accelerating clinical trial matching in oncology

Deep Lens (acquired by Paradigm)

Accelerating clinical trial matching in oncology

Founded 2017 United States Columbus, United States 5 employees Series A Total: $17.20M AI, Health Care +2

General Information

Company Name Deep Lens (acquired by Paradigm)
Founded Year 2017
Location United States Columbus, United States +1
Employees 5
Industries AI, Health Care, Life Sciences +1
Funding Stage Series A
Social

Get notified when Deep Lens (acquired by Paradigm) moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Deep Lens (acquired by Paradigm)

Deep Lens, with the slogan "Accelerating clinical trial matching in oncology," is a digital healthcare company that was established in 2017 and is headquartered in the United States. The company focuses on leveraging AI, machine learning, and life sciences to expedite the recruitment of suitable cancer patients for clinical trials at the time of diagnosis through its proprietary platform, VIPER. Deep Lens' AI-driven cloud platform facilitates collaboration among care teams, trial coordinators, and oncologists, providing visibility into all available trials and enabling groundbreaking cancer research across various cancer types. The company recently secured a $14.00M Series A investment on 08 April 2019, with participation from notable investors including Rev1 Ventures, Service Provider Capital, Tamarind Hill, Sierra Ventures, and Northpond Ventures. Deep Lens operates at the intersection of AI, healthcare, and life sciences, addressing critical challenges in the clinical trial space, particularly within the oncology domain. As the demand for more efficient and precise patient matching in clinical trials grows, Deep Lens stands out as a promising player, poised to have a significant impact on the oncology research landscape.

Taxonomy: Digital Healthcare, Clinical Trials, Oncology, AI-driven Platform, Cancer Patient Recruitment, Digital Pathology Workflow, AI Image Detection, Collaboration Platform, Cloud Storage, API Integration, Pathology Research, Pharmaceuticals, Cancer Research, Pathology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 5
Investor Investor Investor Investor Investor
08 Apr 2019
Seed Round •••••• 3
Investor Investor Investor
27 Sep 2018

Deep Lens (acquired by Paradigm) Alternatives & Competitors

Deep Lens (acquired by Paradigm) vs
Breast Cancer Trials
Breast Cancer Trials Australia

We do the research, so that no more lives are cut short from breast cancer | #nomorelivescutshort

65 employees
Health Care
Deep Lens (acquired by Paradigm) vs
Alliance Foundation Trials, LLC
Alliance Foundation Trials, LLC United States

Seeking to reduce the impact of cancer

49 employees
Biotechnology, Health Care
Deep Lens (acquired by Paradigm) vs
Melanoma and Skin Cancer Trials
Melanoma and Skin Cancer Trials Australia

Conquering melanoma and skin cancer through clinical trials.

16 employees

FAQ About Deep Lens (acquired by Paradigm)

Accelerating clinical trial matching in oncology
Deep Lens (acquired by Paradigm) was founded in 2017.
Deep Lens (acquired by Paradigm) is headquartered in Columbus, United States.
Deep Lens (acquired by Paradigm) operates in the following industries: AI, Health Care, Life Sciences, Machine Learning.
Deep Lens (acquired by Paradigm) has approximately 5 employees.
Deep Lens (acquired by Paradigm) has completed 2 funding rounds, raising a total of $17.20M. The latest funding stage is Series A.
Top alternatives and competitors to Deep Lens (acquired by Paradigm) include Breast Cancer Trials, Alliance Foundation Trials, LLC, Melanoma and Skin Cancer Trials, Neurabot Lab, Cure Leukaemia. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Deep Lens (acquired by Paradigm) and Breast Cancer Trials are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Deep Lens (acquired by Paradigm) and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes